点击蓝字关注我们本周,热点不少。首先看审评审批方面,多个药获批,很值得一提的就是,奥赛康药业1类新药利厄替尼片获批上市;其次是研发方面,多个药取得重要进展,其中,全球第2款PROTAC药物BMS-986365进入Ⅲ期阶段;最后是交易及投融资方面,有不少交易尘埃落定,最大金额的是,强生146亿美元收购Intra-Cellular。本期盘点包括审评审批、研发、交易及投融资三大板块,统计时间为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.